Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MDRNA hopes to create RNAi leader through Cequent acquisition

Executive Summary

MDRNA Inc. has acquired privately held Cequent Pharmaceuticals Inc., a fellow RNAi-focused company. MDRNA will issue shares worth $44mm to Cequent investors, plus an additional $2mm in stock to warrant and option holders. (Based on MDRNA's ten-day average prior to deal announced, it issued approximately 43.1mm shares.)
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies